Effect of NF-κB inhibitor PDTC on VEGF and endostatin expression of mice with Lewis lung cancer

Objective: To investigate the effects of NF-kappa B inhibitor pyrrolidine dithiocarbamate hydrochloride (PDTC) on vascular endothelial growth factor (VEGF) and endostatin expression in mice with Lewis lung cance; and its mechanism. Methods: Mice survival rate and anti-tumor effects were observed in different concentrations of NF-kappa B inhibitor PDTC after the Lewis lung cancer mice model was established. VEGF and endostatin expressions were detected by immunohistochemical assay. Results: Lewis lung cancer was be inhibited by 0.5 mg/kg, 1.5 mg/kg and 3.0 mg/kg of NF-kappa B inhibitor PDTC (P<0.05). Microvessel density (MVD) in 0.5 mg/kg, 1.5 mg/kg and 3.0 mg/kg NF-kappa B inhibitor PDTC groups were significantly lower than the control group (P<0.05). Immunohistochemical assay results showed that VEGF and endostatin expressions in the 0.5 mg/kg, 1.5 mg/kg and 3.0 mg/kg NFK B inhibitor PDTC groups were significantly lower than the control group (P<0.05). Western blot results also showed that NF-kappa B inhibitor PDTC could inhibit VEGF and endostatin expressions in tumor tissues. Conclusions: NF-kappa B inhibitor PDTC can inhibit tumor formation mit-educe tumor angiogeneSis in mice with Lewis lung cancer; and its mechanism maybe associated to VEGF and endostatin down-regulation.